发明名称 Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
摘要 The present invention relates to the compound of formula (I); and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
申请公布号 US9637494(B2) 申请公布日期 2017.05.02
申请号 US201615092707 申请日期 2016.04.07
申请人 Respivert, Ltd. 发明人 King-Underwood John;Ito Kazuhiro;Murray Peter John;Hardy George;Brookfield Frederick Arthur;Brown Christopher John
分类号 A01N43/90;A61K31/519;C07D487/04 主分类号 A01N43/90
代理机构 代理人 Wong Ada O.
主权项 1. A method of treatment of a condition selected from: COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma which comprises administering to a subject in need thereof an effective amount of a compound of formula (I):that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.
地址 Buckinghamshire GB